How does Vanflyta work (mechanism of action)?
Vanflyta (quizartinib) is a targeted anticancer drug that blocks a specific signaling pathway driven by FLT3. It inhibits FLT3 (Fms-like tyrosine kinase 3), a receptor tyrosine kinase that can be abnormally active in FLT3-mutated acute myeloid leukemia (AML). By shutting down FLT3 signaling, quizartinib helps stop downstream signals that support leukemia cell growth and survival.
What FLT3 pathway is it targeting in AML?
FLT3 is a cell-surface kinase that, when mutated or overactive, promotes proliferation and survival of AML blasts. Vanflyta’s action is to inhibit that FLT3-driven signaling, reducing the signals leukemia cells rely on to keep growing.
Is Vanflyta a chemotherapy or a targeted therapy?
Vanflyta is a targeted therapy aimed at FLT3 rather than a traditional cytotoxic chemotherapy. Its intended mechanism is receptor/kinase inhibition (FLT3), which is the basis for its selectivity toward FLT3-driven disease.
What happens to leukemia cells when FLT3 is blocked?
When FLT3 is inhibited, leukemia cells receive fewer growth/survival signals from that receptor. The practical effect is reduced ability to proliferate and increased susceptibility to treatment-mediated cell death for FLT3-mutated AML.
Sources
No sources were provided in the prompt to cite. If you share a link or document that states Vanflyta’s mechanism of action, I can incorporate it and cite it precisely.